Coen Steven P. 4

What Happened

• Coen Steven P., Chief Financial Officer of Ginkgo Bioworks (DNA), converted restricted stock units (RSUs) into common shares on March 13, 2026 and sold 708 shares in an open-market transaction on March 16, 2026.
• The March 16 sale was 708 shares at $6.74 each for a total proceeds of $4,768. The Form 4 also reports conversions (exercise/settlement of RSUs) on March 13 of 1,174 and 312 RSUs into common stock.
• Footnotes indicate the sale was to cover tax withholding associated with RSU vesting (a “sell-to-cover”), which is routine and not a discretionary trade by the reporting person.

Key Details

• Transaction dates and prices:
  • Mar 13, 2026: conversion/exercise (RSU settlement) of 1,174 shares and 312 shares (reported as derivative conversions).
  • Mar 16, 2026: open-market sale of 708 shares at $6.74 (total $4,768).
• Shares owned after transaction: not specified in the filing.
• Relevant footnotes:
  • F1: Each RSU converts to one share of Class A common stock.
  • F2: The sale(s) were to cover tax withholding on vesting (sell-to-cover), not discretionary sales.
  • F3/F4: Two different RSU vesting schedules apply to the grants (one with 25% cliff then monthly vesting; one with 2/48 vested at first date then monthly).
• Filing info: Form filed March 18, 2026 (reporting period includes the March 13 conversions); the filing lists the reporter as CFO.

Context

• These were conversions of RSUs (not new purchases). The later open-market sale appears to be a routine sell-to-cover to satisfy tax withholding obligations following vesting. Such transactions are common and typically reflect tax mechanics rather than a statement of the insider’s market outlook.
• The Form shows both the acquisition (conversion/settlement) and disposal entries for the RSU-related shares; a portion was sold on Mar 16 to meet withholding requirements.